JP2021020889A - ミエリン形成を促進するための組成物 - Google Patents
ミエリン形成を促進するための組成物 Download PDFInfo
- Publication number
- JP2021020889A JP2021020889A JP2020091695A JP2020091695A JP2021020889A JP 2021020889 A JP2021020889 A JP 2021020889A JP 2020091695 A JP2020091695 A JP 2020091695A JP 2020091695 A JP2020091695 A JP 2020091695A JP 2021020889 A JP2021020889 A JP 2021020889A
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- composition
- myelin formation
- connexin
- promoting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 102000006386 Myelin Proteins Human genes 0.000 title claims abstract description 58
- 108010083674 Myelin Proteins Proteins 0.000 title claims abstract description 58
- 210000005012 myelin Anatomy 0.000 title claims abstract description 58
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 48
- 230000001737 promoting effect Effects 0.000 title claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 98
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims abstract description 38
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229940117916 cinnamic aldehyde Drugs 0.000 claims abstract description 38
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 33
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 33
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 33
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 33
- 229940025878 hesperidin Drugs 0.000 claims abstract description 33
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 33
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 33
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 33
- HXTFHSYLYXVTHC-AJHDJQPGSA-N narirutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O1 HXTFHSYLYXVTHC-AJHDJQPGSA-N 0.000 claims abstract description 32
- HXTFHSYLYXVTHC-ZPHOTFPESA-N narirutin Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](Oc3cc(O)c4C(=O)C[C@H](Oc4c3)c5ccc(O)cc5)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O HXTFHSYLYXVTHC-ZPHOTFPESA-N 0.000 claims abstract description 32
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- -1 cinnamyl ester Chemical class 0.000 claims abstract description 13
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims abstract description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 44
- 244000080208 Canella winterana Species 0.000 claims description 17
- 235000008499 Canella winterana Nutrition 0.000 claims description 17
- 229940017545 cinnamon bark Drugs 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000010227 chenpi Substances 0.000 claims description 10
- 229940000425 combination drug Drugs 0.000 claims description 5
- 241000555678 Citrus unshiu Species 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 4
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 claims description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 abstract description 23
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 abstract description 23
- 229930016911 cinnamic acid Natural products 0.000 abstract description 23
- 235000013985 cinnamic acid Nutrition 0.000 abstract description 23
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 abstract description 23
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 abstract description 14
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 abstract description 7
- 230000014509 gene expression Effects 0.000 description 53
- 210000004248 oligodendroglia Anatomy 0.000 description 31
- 238000011282 treatment Methods 0.000 description 27
- 210000004556 brain Anatomy 0.000 description 24
- 208000016192 Demyelinating disease Diseases 0.000 description 22
- 102100039288 Gap junction gamma-2 protein Human genes 0.000 description 20
- 108010015440 connexin 47 Proteins 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 108010069241 Connexin 43 Proteins 0.000 description 17
- 102000001045 Connexin 43 Human genes 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000002265 prevention Effects 0.000 description 17
- 206010012305 Demyelination Diseases 0.000 description 16
- 102100037260 Gap junction beta-1 protein Human genes 0.000 description 15
- 108010015416 connexin 32 Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 210000001130 astrocyte Anatomy 0.000 description 13
- 230000023105 myelination Effects 0.000 description 12
- 102000010970 Connexin Human genes 0.000 description 11
- 108050001175 Connexin Proteins 0.000 description 11
- 230000002195 synergetic effect Effects 0.000 description 11
- 108010069176 Connexin 30 Proteins 0.000 description 10
- 102000001051 Connexin 30 Human genes 0.000 description 10
- 206010012289 Dementia Diseases 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 201000010374 Down Syndrome Diseases 0.000 description 9
- 206010044688 Trisomy 21 Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000002033 PVDF binder Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 235000017803 cinnamon Nutrition 0.000 description 7
- 230000003920 cognitive function Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000003976 gap junction Anatomy 0.000 description 6
- 230000035800 maturation Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 210000004885 white matter Anatomy 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical class C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000051366 Glycosyltransferases Human genes 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000034800 Leukoencephalopathies Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000001373 regressive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000002477 vacuolizing effect Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 102100036076 Glycerophosphocholine cholinephosphodiesterase ENPP6 Human genes 0.000 description 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000876254 Homo sapiens Glycerophosphocholine cholinephosphodiesterase ENPP6 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010056332 Panencephalitis Diseases 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000009212 ren-shen-yang-rong-tang Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Abstract
Description
第1の有効成分としての、グリセロホスホコリン及びその薬理的に許容された塩から成る群から選択された少なくとも一種の化合物と、
第2の有効成分としての、ヘスペリジン、ナリルチン、及びこれらの薬理的に許容された塩から成る群から選択された少なくとも一種の化合物と、
第3の有効成分としての、シンナミルエステル、シンナミルアルコール、シンナムアルデヒド、ケイ皮酸、及びこれらの薬理的に許容された塩から成る群から選択された少なくとも一種の化合物と
を含む、ミエリン形成を促進するための組成物に関する。
第1の有効成分としての、グリセロホスホコリン及びその薬理的に許容された塩から成る群から選択された少なくとも一種の化合物と、
第2の有効成分としての、ヘスペリジン、ナリルチン、及びこれらの薬理的に許容された塩から成る群から選択された少なくとも一種の化合物と、
第3の有効成分としての、シンナミルエステル、シンナミルアルコール、シンナムアルデヒド、ケイ皮酸、及びこれらの薬理的に許容された塩から成る群から選択された少なくとも一種の化合物と
を含む。主に第3の有効成分の作用により、アルツハイマー病の発症によってアップレギュレーションされたコネキシン43の発現量が減少し、主に第1の有効成分と第2の有効成分との併用により、コネキシン32の発現量が増加し、第1の有効成分と第2の有効成分と第3の有効成分との相乗効果により、コネキシン47の発現量が顕著に増加するとともにオリゴデンドロサイトの成熟・分化・生存ひいてはミエリン形成のカギを握るp−21.5kDaMBPの発現量が顕著に増加する。また、このミエリン形成のカギを握るp−21.5kDaMBPの発現量の顕著な増加のため、本発明の組成物は、アルツハイマー病の治療及び/又は予防に限定されず、ミエリン形成の障害を発症する疾患の治療及び/又は予防のために広く有効利用することができる
(A)動物・飼育環境
以下の実験においてアルツハイマー病の病態モデルマウスとして使用したヒトのスウェーデン変位型APP(APPK670N/M671L)遺伝子を導入した遺伝子改変マウスTg2576は、米国のThe Jackson Laboratoryから入手した。入手したTg2576マウスを、室温25±1℃、相対湿度55±1%の飼育施設で、12時間/12時間の明暗の照明サイクル(7:00点灯、19:00消灯)の環境下で飼育した。なお、この動物実験は、実験動物の適正な使用及び管理を定めたNIHガイドラインに基づき作成された慶應義塾大学動物実験ガイドラインに則り、同大学内動物実験施設で行った。
15月齢のTg2576マウス(平均体重30g)を4つの群に分け、それぞれの群に以下の練り餌さを与えて1か月間飼育した。なお、以下に示す練り餌さの量はマウス一匹に対して一日に与えた量であり、各マウスが1日で食べきっていることを確認した。
対照:5.26gの飼料の練り餌さ。
GHN投与:0.833mgのα−GPC(G)と、合計で1.458mgのヘスペリジン(H)とナリルチン(N)とを還元麦芽糖水飴、でんぷん等の慣用の添加物と混合した組成物の20mgを5.26gの飼料に混ぜた練り餌さ。
C投与:桂皮粉末(シンナムアルデヒドを1.3質量%、ケイ皮酸を0.025質量%含有)の5mg(シンナムアルデヒドとケイ皮酸とを合計で0.06625mg)を5.26gの飼料に混ぜた練り餌さ。
GHN+C投与:0.833mgのα−GPC(G)と、合計で1.458mgのヘスペリジン(H)とナリルチン(N)とを還元麦芽糖水飴、でんぷん等の慣用の添加物と混合した組成物の20mgと、桂皮粉末(シンナムアルデヒドを1.3質量%、ケイ皮酸を0.025質量%含有)の5mg(シンナムアルデヒドとケイ皮酸とを合計で0.06625mg)とを5.26gの飼料に混ぜた練り餌さ。
1か月の飼育後に、対照マウス、GHN投与マウス、C投与マウス、及びGHN+C投与マウスを、イソフルラン(和光純薬工業株式会社)を用いた吸引麻酔下で安楽死させ、直ちに開頭した後、全脳を摘出した。摘出した脳の1/2の重さを測定し、脳重量1gにつき、氷冷したリン酸緩衝生理食塩水(PBS)を10mL添加し、さらに、100xプロテアーゼ阻害剤カクテル(メルク株式会社)の100倍希釈液に10容量%のRIPAバッファー(20mMのトリス(ヒドロキシメチル)アミノメタン(Tris)(ナカライテスク株式会社)、150mMのNaCl(シグマアルドリッチジャパン合同会社)、1%のポリ(オキシエチレン)オクチルフェニルエーテル(商品名Tx−100;シグマアルドリッチジャパン合同会社)、1%のデオキシコール酸ナトリウム(シグマアルドリッチジャパン合同会社)、0.1%のラウリル硫酸ナトリウム(SDS)(シグマアルドリッチジャパン合同会社))を添加した液を10mL添加した後、ホモジナイザーを用いて脳を可溶化した。得られた脳ホモジネート懸濁液を1.5mLのエッペンドルフチューブに回収し、4℃、20000×Gの条件で20分間遠心分離した。遠心分離後、上澄み液を可溶性画分、沈渣を不溶性画分として分離し、−80℃で保存した。
上記(C)工程にて得られた可溶性画分をLaemmliサンプルバッファー(メルクミリポア社:62.5mM Tris−HCl(pH6.8)、25% グリセロール、2% SDS、0.01% ブロモフェノールブルー含有)で4倍に希釈し、100℃の恒温槽中に10分間放置して、SDS−PAGE用サンプルを得た。
ポリフッ化ビニリデン(PVDF)膜(商品名;immobilon−p:孔径0.45μm:メルクミリポア社)を転写液(31mM Tris(ナカライテスク株式会社)、0.24M グリシン(シグマアルドリッチジャパン合同会社)、20% メタノール(和光純薬工業株式会社))中に導入して15分間振とうし、回収したPVDF膜と上記(D)工程にて得られた電気泳動後のゲルとを接触させ、室温にて20mA/cm2の条件下で電流を流し、タンパク質をPVDF膜に転写した。転写後のPVDF膜に、10倍希釈した10xトリス緩衝生理食塩水(TBS)(0.5M Tris(pH8.1)(ナカライテスク株式会社)、1.5M NaCl(シグマアルドリッチジャパン合同会社)、1N 塩酸(和光純薬工業株式会社))に5%のスキムミルク(株式会社Defco)を溶解させたブロッキングバッファーを用いて、1時間室温にてブロッキング処理を施した。
図2は、内部標準のGAPDHにて正規化されたコネキシン30の存在量を、対照マウスの脳における存在量を1とした存在量比の形式で示した図である。図2から把握されるように、コネキシン30の発現量は、GHN投与及びC投与によってそれぞれ増加したものの、顕著な発現量の増加は認められなかった。また、GHN+C投与によるコネキシン30発現の増加量は、GHN投与による増加分にC投与による増加分を加算した量にほぼ相当し、加算効果が認められた。
ダウン症のモデルマウスを用いたダウン症の発症過程の遺伝子発現研究によって、オリゴデンドロサイトとミエリンの異常が報告されている(2016 Mar 16;89(6):1208−1222. doi: 10.1016/j.neuron.2016.01.042)。一方、本発明の組成物によりミエリン形成のカギを握るp−21.5kDaMBPの発現量が顕著に増加するため、本発明の組成物がダウン症の改善のために有効であると期待される。そのため、退行症状を有し器質的合併症を有していない成人のダウン症発症者7名に対して、一日当たり、α−GPCを40mg、ヘスペリジンとナリルチンとを合計で70mg、及び、ケイ皮酸とシンナムアルデヒドを合計で0.6mgの量で含む桂皮エキスパウダーを含む組成物を6か月間服用させ、社会性に対する退行症状と認知機能の評価とを行った。
Claims (9)
- 第1の有効成分としての、グリセロホスホコリン及びその薬理的に許容された塩から成る群から選択された少なくとも一種の化合物と、
第2の有効成分としての、ヘスペリジン、ナリルチン、及びこれらの薬理的に許容された塩から成る群から選択された少なくとも一種の化合物と、
第3の有効成分としての、シンナミルエステル、シンナミルアルコール、シンナムアルデヒド、ケイ皮酸、及びこれらの薬理的に許容された塩から成る群から選択された少なくとも一種の化合物と
を含む、ミエリン形成を促進するための組成物。 - アルツハイマー病の治療及び/又は予防のための組成物である、請求項1に記載のミエリン形成を促進するための組成物。
- 成人一人当たりの一日当たりの投与量として、10〜200mgの第1の有効成分と、30〜350mgの第2の有効成分と、0.6〜15mgの第3の有効成分とを含む、請求項1又は2に記載のミエリン形成を促進するための組成物。
- 第2の有効成分としてヘスペリジンとナリルチンとを含む、請求項1〜3のいずれか1項に記載のミエリン形成を促進するための組成物。
- 第2の有効成分の少なくとも一部を、ウンシュウミカン由来の陳皮、該陳皮の抽出物、ジャバラ、ジャバラの抽出物、及びこれらの混合物のうちのいずれかの形態で含む、請求項1〜4のいずれか1項に記載のミエリン形成を促進するための組成物。
- 第3の有効成分の少なくとも一部を、桂皮又は桂皮の抽出物の形態で含む、請求項1〜5のいずれか1項に記載のミエリン形成を促進するための組成物。
- 第1の有効成分、第2の有効成分、及び第3の有効成分の全てを含む配合剤として製剤化される、請求項1〜6のいずれか1項に記載のミエリン形成を促進するための組成物。
- 第1の有効成分、第2の有効成分及び第3の有効成分のうちのいずれか一つ或いは2つを含む複数の剤から成るキットとして製剤化される、請求項1〜6のいずれか1項に記載のミエリン形成を促進するための組成物。
- 健康食品として投与される、請求項1〜8のいずれか1項に記載のミエリン形成を促進するための組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019138278 | 2019-07-26 | ||
JP2019138278 | 2019-07-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021020889A true JP2021020889A (ja) | 2021-02-18 |
JP7298919B2 JP7298919B2 (ja) | 2023-06-27 |
Family
ID=74574282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020091695A Active JP7298919B2 (ja) | 2019-07-26 | 2020-05-26 | ミエリン形成を促進するための組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7298919B2 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018190146A1 (ja) * | 2017-04-12 | 2018-10-18 | 株式会社グロービア | アルツハイマー病の治療及び/又は予防のための組成物 |
-
2020
- 2020-05-26 JP JP2020091695A patent/JP7298919B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018190146A1 (ja) * | 2017-04-12 | 2018-10-18 | 株式会社グロービア | アルツハイマー病の治療及び/又は予防のための組成物 |
Non-Patent Citations (2)
Title |
---|
BIOMED RESEARCH INTERNATIONAL, vol. Vol.2018, Article ID 3570830, JPN6023016459, 29 August 2018 (2018-08-29), pages 1 - 9, ISSN: 0005044742 * |
NEUROBIOLOGY OF DISEASE, vol. 124, JPN7023001591, 19 December 2018 (2018-12-19), pages 379 - 395, ISSN: 0005044741 * |
Also Published As
Publication number | Publication date |
---|---|
TW202114705A (zh) | 2021-04-16 |
JP7298919B2 (ja) | 2023-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8338382B2 (en) | Method of treating impaired mitochondrial function | |
EP1032403B1 (en) | Nutritional supplement for cerebral metabolic insufficiencies | |
Wang et al. | S 24795 limits β-amyloid–α7 nicotinic receptor interaction and reduces Alzheimer's disease-like pathologies | |
JP6878565B2 (ja) | 乳酸菌による大脳基底核疾患、または、チック障害を治療または予防するための薬剤 | |
KR20110057550A (ko) | 치매, 치매관련 질환의 예방/치료 및 인지기능장애 개선에 효과가 있는 유산균 발효 산물, 이의 제조방법 및 용도 | |
EP2448412B1 (en) | Chromium complexes as enhancers of brain glucose transporters | |
US9254280B2 (en) | Medical food for cognitive decline | |
JP2019123748A (ja) | アミロイドβのガランタミンクリアランス | |
JP6873504B2 (ja) | アルツハイマー病の治療及び/又は予防のための組成物 | |
JP2021020889A (ja) | ミエリン形成を促進するための組成物 | |
US20230078820A1 (en) | Fenfluramine for treatment of demyelinating diseases and conditions | |
KR20200121495A (ko) | 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 | |
TWI836087B (zh) | 用以促進髓鞘質形成的組成物 | |
KR102404844B1 (ko) | 나트륨 부티레이트를 포함하는 쇼그렌 증후군의 예방 및 치료용 조성물 | |
WO2023120425A1 (ja) | 脳機能改善剤 | |
Early | Diffusion Tensor Mr Imaging for Evaluation of Fronto-Subcortical Neural Pathway Changes in Parkinson's Disease With Dementia | |
JP5820127B2 (ja) | アミロイド線維の形成を伴う神経変性疾患の予防・改善薬 | |
JP2019094263A (ja) | アルツハイマー病の治療予防剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20200605 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230328 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230518 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7298919 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |